LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2025
LifeVantage (Nasdaq: LFVN) reported strong financial results for Q4 and fiscal year 2025. Q4 revenue increased 12.6% to $55.1 million, with the Americas growing 14.1% and Asia/Pacific & Europe up 7.6%. Full fiscal year 2025 revenue rose 14.2% to $228.5 million, with net income per diluted share of $0.75 compared to $0.23 in 2024.
The company maintained a strong balance sheet with $20.2 million in cash and no debt. Key highlights include adjusted EBITDA of $22.1 million (up 30.3%) and successful international expansion with the MindBody System rollout. The company declared a dividend of $0.045 per share and provided FY2026 guidance projecting revenue between $225-240 million and adjusted earnings per share of $1.00-1.15.
LifeVantage (Nasdaq: LFVN) ha pubblicato solidi risultati finanziari per il quarto trimestre e l'esercizio 2025. I ricavi del Q4 sono saliti del 12,6% a 55,1 milioni di dollari, con le Americhe in crescita del 14,1% e Asia/Pacifico & Europa in aumento del 7,6%. L'intero esercizio 2025 ha registrato ricavi in crescita del 14,2% a 228,5 milioni di dollari e un utile netto per azione diluita di 0,75$ rispetto a 0,23$ nel 2024.
L'azienda mantiene un bilancio solido con 20,2 milioni di dollari di liquidità e senza debiti. Tra i punti salienti: un EBITDA rettificato di 22,1 milioni di dollari (in aumento del 30,3%) e l'espansione internazionale riuscita grazie al lancio del MindBody System. È stato dichiarato un dividendo di 0,045$ per azione e la guidance per il FY2026 indica ricavi previsti tra 225-240 milioni di dollari e utili rettificati per azione compresi tra 1,00 e 1,15$.
LifeVantage (Nasdaq: LFVN) presentó sólidos resultados financieros del cuarto trimestre y del año fiscal 2025. Los ingresos del Q4 aumentaron un 12,6% hasta 55,1 millones de dólares, con las Américas creciendo un 14,1% y Asia/Pacífico & Europa subiendo un 7,6%. Los ingresos del año fiscal 2025 crecieron un 14,2% hasta 228,5 millones de dólares, y el beneficio neto por acción diluida fue de 0,75$ frente a 0,23$ en 2024.
La compañía mantiene un balance sólido con 20,2 millones de dólares en efectivo y sin deuda. Puntos clave: EBITDA ajustado de 22,1 millones (subida del 30,3%) y una exitosa expansión internacional con el despliegue del MindBody System. Se declaró un dividendo de 0,045$ por acción y la guía para el FY2026 prevé ingresos entre 225-240 millones de dólares y beneficios ajustados por acción de 1,00-1,15$.
LifeVantage (Nasdaq: LFVN)는 2025 회계연도 4분기 및 연간 실적에서 견조한 성과를 발표했습니다. 4분기 매출은 12.6% 증가한 5,510만 달러를 기록했으며, 미주 지역은 14.1% 성장, 아시아/태평양 및 유럽은 7.6% 증가했습니다. 2025 회계연도 전체 매출은 14.2% 증가한 2억2,850만 달러였고, 희석 주당순이익은 0.75달러로 2024년 0.23달러에서 상승했습니다.
회사는 현금 2,020만 달러와 무차입 상태로 건전한 재무구조를 유지하고 있습니다. 주요 내용으로는 조정 EBITDA가 2,210만 달러(30.3% 증가)를 기록했고, MindBody System 도입을 통한 성공적인 국제 확장이 있습니다. 주당 0.045달러의 배당을 선언했으며 FY2026 가이던스는 매출을 2억2,500만~2억4,000만 달러로, 조정 주당순이익을 1.00~1.15달러로 제시했습니다.
LifeVantage (Nasdaq: LFVN) a publié de solides résultats financiers pour le quatrième trimestre et l'exercice 2025. Le chiffre d'affaires du T4 a augmenté de 12,6% à 55,1 millions de dollars, les Amériques progressant de 14,1% et l'Asie/Pacifique & Europe de 7,6%. Sur l'ensemble de l'exercice 2025, le chiffre d'affaires a crû de 14,2% à 228,5 millions de dollars, le bénéfice net dilué par action s'élevant à 0,75$ contre 0,23$ en 2024.
L'entreprise conserve un bilan solide avec 20,2 millions de dollars de trésorerie et aucune dette. Faits marquants : EBITDA ajusté de 22,1 millions (en hausse de 30,3%) et extension internationale réussie grâce au déploiement du MindBody System. Un dividende de 0,045$ par action a été déclaré ; les prévisions pour l'exercice 2026 tablent sur des revenus entre 225 et 240 millions de dollars et un bénéfice ajusté par action de 1,00 à 1,15$.
LifeVantage (Nasdaq: LFVN) meldete starke Finanzergebnisse für das vierte Quartal und das Geschäftsjahr 2025. Der Umsatz im Q4 stieg um 12,6% auf 55,1 Mio. USD, wobei die Americas um 14,1% und Asien/Pazifik & Europa um 7,6% wuchsen. Für das gesamte Geschäftsjahr 2025 erhöhten sich die Erlöse um 14,2% auf 228,5 Mio. USD, das verwässerte Ergebnis je Aktie lag bei 0,75 USD gegenüber 0,23 USD in 2024.
Das Unternehmen verfügt über eine starke Bilanz mit 20,2 Mio. USD Cash und keiner Verschuldung. Wichtige Eckdaten: bereinigtes EBITDA von 22,1 Mio. USD (plus 30,3%) und eine erfolgreiche Internationalisierung durch die Einführung des MindBody Systems. Es wurde eine Dividende von 0,045 USD je Aktie beschlossen; die FY2026-Prognose sieht Umsätze von 225–240 Mio. USD und bereinigtes Ergebnis je Aktie von 1,00–1,15 USD vor.
- Revenue growth of 14.2% to $228.5 million in FY2025
- Net income per diluted share tripled from $0.23 to $0.75 year-over-year
- Adjusted EBITDA increased 30.3% to $22.1 million
- Strong balance sheet with $20.2 million cash and zero debt
- International business returned to growth after three years
- Gross margin improved to 80.4% from 79.3% year-over-year
- Active share repurchase program with $17.3 million remaining
- SG&A expenses increased to $69.2 million from $68.5 million
- Operating income margin remains relatively low at 5.3%
- Asia/Pacific & Europe revenue decreased 9.4% for full fiscal year
- Commissions and incentives expense increased to 44.7% of revenue from 42.9%
- Q4 operating income declined to $2.1 million from $2.9 million year-over-year
Insights
LifeVantage delivered strong FY2025 results with 14.2% revenue growth and 227% EPS increase, showing operational efficiency and international recovery.
LifeVantage capped off a stellar fiscal year 2025 with impressive Q4 results, demonstrating robust momentum across key metrics. Fourth-quarter revenue jumped
The full fiscal year 2025 results paint an even more compelling picture. Total revenue increased
The company's gross margin expanded by 110 basis points to
The balance sheet remains healthy with
SALT LAKE CITY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its fourth quarter and full fiscal year ended June 30, 2025.
Fourth Quarter Fiscal 2025 Summary*:
- Revenue of
$55.1 million , an increase of12.6% from the prior year period. Excluding the impact of foreign currency fluctuations, fourth quarter revenue increased approximately11.6% ; - Revenue in the Americas increased
14.1% and revenue in Asia/Pacific & Europe increased7.6% . Excluding foreign currency fluctuations, fourth quarter revenue in Asia/Pacific & Europe increased1.6% ; - Net income per diluted share was
$0.15 , versus$0.10 per diluted share a year ago; - Adjusted earnings per diluted share were
$0.17 , compared to$0.14 a year ago; and - Adjusted EBITDA of
$4.8 million was flat compared to a year ago.
* All comparisons are on a year over year basis and compare the fourth quarter of fiscal 2025 to the fourth quarter of fiscal 2024, unless otherwise noted.
Fiscal Year 2025 Summary**:
- Revenue of
$228.5 million , an increase of14.2% . Excluding the negative impact of foreign currency fluctuations, fiscal year 2025 revenue increased approximately14.4% ; - Revenue in the Americas increased
21.5% , and revenue in Asia/Pacific & Europe decreased9.4% ; - Net income per diluted share was
$0.75 , compared to$0.23 in fiscal 2024; - Adjusted earnings per diluted share was
$0.82 , compared to$0.59 in fiscal 2024; - Adjusted EBITDA increased
30.3% , to$22.1 million ; - Repurchased 0.3 million shares for
$3.1 million ; and - Strong balance sheet with
$20.2 million of cash and no debt.
**All growth rates compare fiscal 2025 to fiscal 2024.
"Fourth quarter results capped off a strong fiscal 2025 as we delivered revenue growth of approximately
Fourth Quarter Fiscal 2025 Results
For the fourth fiscal quarter ended June 30, 2025, the Company reported revenue of
Gross profit for the fourth quarter of fiscal 2025 was
Commissions and incentives expense for the fourth quarter of fiscal 2025 was
Selling, general and administrative expense (SG&A) for the fourth quarter of fiscal 2025 was
Operating income for the fourth quarter of fiscal 2025 was
Net income for the fourth quarter of fiscal 2025 was
Adjusted EBITDA was
Fiscal 2025 Full Year Results
For the fiscal year ended June 30, 2025, the Company reported net revenue of
Gross profit during fiscal 2025 was
Commissions and incentives expense for fiscal 2025 was
SG&A expense for fiscal 2025 was
Operating income for fiscal 2025 was
Net income for fiscal 2025 was
Adjusted EBITDA was
Share Repurchase
During the fourth quarter of fiscal 2025, the Company repurchased 0.2 million of its common shares for an aggregate price of approximately
Balance Sheet & Liquidity
The Company generated
Dividend Announcement
On August 28, 2025, the Company announced the declaration of a cash dividend of
Fiscal Year 2026 Guidance
The Company expects to generate revenue in the range of
Conference Call Information
The Company will hold an investor conference call today at 2:30 p.m. MST (4:30 p.m. EST). Investors interested in participating in the live call can dial (877) 704-4453 from the U.S. or international callers can dial (201) 389-0920. A telephone replay will be available approximately two hours after the call concludes and will be available through Thursday, September 18, 2025, by dialing (844) 512-2921 from the U.S. and entering confirmation code 13755010, or (412) 317-6671 from international locations, and entering confirmation code 13755010.
There will also be a simultaneous, live webcast available on the Investor Relations section of the Company's web site at https://lifevantage.gcs-web.com/events-and-presentations or directly at https://viavid.webcasts.com/starthere.jsp?ei=1727833&tp_key=a40e7ecfbe. The webcast will be archived for approximately 30 days.
About LifeVantage Corporation
LifeVantage Corporation (Nasdaq: LFVN), the Activation company, is a pioneer in nutrigenomics—the study of how nutrition and naturally occurring compounds can unlock your genes and the health coded within. Our products work with your unique biology and help your body make what it needs for health. The line of scientifically validated activators includes the flagship Protandim® family of products, TrueScience® Liquid Collagen, the newest MindBody GLP-1 System™, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System®, as well as AXIO® nootropic energy drink mixes, the full TrueScience® line of skin and hair care products, and Petandim®, a pet supplement formulated to combat oxidative stress in dogs. Our independent Consultants sell our products to Customers and share the business opportunity with entrepreneurs seeking to begin their own business. LifeVantage was founded in 2003 and is headquartered in Lehi, Utah. For more information, visit www.lifevantage.com.
Cautionary Note Regarding Forward Looking Statements
This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believe," "will," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates," "look forward to," "goal," “may be,” and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The declaration and/or payment of a dividend during any quarter provides no assurance as to future dividends, and the timing and amount of future dividends, if any, could vary significantly in comparison both to past dividends and to current expectations. Examples of forward-looking statements include, but are not limited to, expected financial performance, including revenue margins, statements we make regarding executing against and the benefits of our key initiatives, future growth, including geographic and product expansion, and expected dividend payments in future quarters. Such forward-looking statements are not guarantees of performance and the Company's actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company's current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, further deterioration to the global economic and operating environments, as well as those discussed in greater detail in the Company's Annual Report on Form 10-K and the Company's Quarterly Report on Form 10-Q under the caption "Risk Factors," and in other documents filed by the Company from time to time with the Securities and Exchange Commission (the “SEC”). The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by law.
About Non-GAAP Financial Measures
We define Non-GAAP EBITDA as earnings before interest expense, income taxes, depreciation and amortization and Non-GAAP Adjusted EBITDA as earnings before interest expense, income taxes, depreciation and amortization, stock compensation expense, other income, net, and certain other adjustments. Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. We define Non-GAAP Net Income as GAAP net income less certain tax adjusted non-recurring one-time expenses incurred during the period and Non-GAAP Earnings per Share as Non-GAAP Net Income divided by weighted-average shares outstanding.
We are presenting Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share because management believes that they provide additional ways to view our operations when considered with both our GAAP results and the reconciliation to net income, which we believe provides a more complete understanding of our business than could be obtained absent this disclosure. Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share are presented solely as supplemental disclosure because: (i) we believe these measures are a useful tool for investors to assess the operating performance of the business without the effect of these items; (ii) we believe that investors will find this data useful in assessing shareholder value; and (iii) we use Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings Per Share internally as benchmarks to evaluate our operating performance or compare our performance to that of our competitors. The use of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings per Share has limitations and you should not consider these measures in isolation from or as an alternative to the relevant GAAP measure of net income prepared in accordance with GAAP, or as a measure of profitability or liquidity.
The tables set forth below present reconciliations of Non-GAAP EBITDA, Non-GAAP Adjusted EBITDA, Non-GAAP Net Income and Non-GAAP Earnings per Share, which are non-GAAP financial measures to Net Income and Earnings per Share, our most directly comparable financial measures presented in accordance with GAAP.
Investor Relations Contact:
Reed Anderson, ICR
(646) 277-1260
reed.anderson@icrinc.com
| LIFEVANTAGE CORPORATION AND SUBSIDIARIES | |||||||
| CONSOLIDATED BALANCE SHEETS | |||||||
| As of | |||||||
| (In thousands, except per share data) | June 30, 2025 | June 30, 2024 | |||||
| ASSETS | |||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 20,201 | $ | 16,886 | |||
| Accounts receivable | 3,294 | 2,949 | |||||
| Income tax receivable | 635 | 313 | |||||
| Inventory | 20,669 | 15,055 | |||||
| Prepaid expenses and other | 6,095 | 2,443 | |||||
| Total current assets | 50,894 | 37,646 | |||||
| Property and equipment, net | 6,207 | 7,813 | |||||
| Right-of-use assets | 8,041 | 9,569 | |||||
| Intangible assets, net | 245 | 323 | |||||
| Deferred income tax asset | 5,970 | 4,268 | |||||
| Other long-term assets | 601 | 680 | |||||
| TOTAL ASSETS | $ | 71,958 | $ | 60,299 | |||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||
| Current liabilities | |||||||
| Accounts payable | $ | 4,600 | $ | 5,853 | |||
| Commissions payable | 7,237 | 6,569 | |||||
| Income tax payable | — | 202 | |||||
| Lease liabilities | 1,867 | 1,811 | |||||
| Other accrued expenses | 13,513 | 7,874 | |||||
| Total current liabilities | 27,217 | 22,309 | |||||
| Long-term lease liabilities | 9,811 | 11,801 | |||||
| Other long-term liabilities | 289 | 198 | |||||
| Total liabilities | 37,317 | 34,308 | |||||
| Commitments and contingencies | |||||||
| Stockholders' equity | |||||||
| Preferred stock — par value | — | — | |||||
| Common stock — par value | 1 | 1 | |||||
| Additional paid-in capital | 139,962 | 136,644 | |||||
| Accumulated deficit | (104,147 | ) | (108,738 | ) | |||
| Accumulated other comprehensive income | (1,175 | ) | (1,916 | ) | |||
| Total stockholders’ equity | 34,641 | 25,991 | |||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 71,958 | $ | 60,299 | |||
| LIFEVANTAGE CORPORATION AND SUBSIDIARIES | |||||||||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS | |||||||||||||||
| For the Three Months Ended June 30, (unaudited) | Fiscal Year Ended June 30, | ||||||||||||||
| (In thousands, except per share data) | 2025 | 2024 | 2025 | 2024 | |||||||||||
| Revenue, net | $ | 55,114 | $ | 48,931 | $ | 228,530 | $ | 200,164 | |||||||
| Cost of sales | 11,065 | 10,022 | 44,864 | 41,440 | |||||||||||
| Gross profit | 44,049 | 38,909 | 183,666 | 158,724 | |||||||||||
| Operating expenses: | |||||||||||||||
| Commissions and incentives | 23,222 | 21,979 | 102,260 | 85,920 | |||||||||||
| Selling, general and administrative | 18,679 | 14,020 | 69,207 | 68,472 | |||||||||||
| Total operating expenses | 41,901 | 35,999 | 171,467 | 154,392 | |||||||||||
| Operating income | 2,148 | 2,910 | 12,199 | 4,332 | |||||||||||
| Other expense: | |||||||||||||||
| Interest income, net | 111 | 78 | 431 | 430 | |||||||||||
| Other expense, net | 137 | (277 | ) | (387 | ) | (412 | ) | ||||||||
| Total other income, net | 248 | (199 | ) | 44 | 18 | ||||||||||
| Income before income taxes | 2,396 | 2,711 | 12,243 | 4,350 | |||||||||||
| Income tax expense | (437 | ) | (1,406 | ) | (2,438 | ) | (1,413 | ) | |||||||
| Net income | $ | 1,959 | $ | 1,305 | $ | 9,805 | $ | 2,937 | |||||||
| Net income per share: | |||||||||||||||
| Basic | $ | 0.16 | $ | 0.11 | $ | 0.80 | $ | 0.24 | |||||||
| Diluted | $ | 0.15 | $ | 0.10 | $ | 0.75 | $ | 0.23 | |||||||
| Weighted-average shares outstanding: | |||||||||||||||
| Basic | 12,326 | 12,256 | 12,251 | 12,458 | |||||||||||
| Diluted | 13,128 | 12,867 | 12,987 | 12,986 | |||||||||||
| LIFEVANTAGE CORPORATION AND SUBSIDIARIES | ||||||||||||||||||||||||
| Revenue by Region | ||||||||||||||||||||||||
| Three Months Ended June 30, (unaudited) | Fiscal Year Ended June 30, | |||||||||||||||||||||||
| (In thousands) | 2025 | 2024 | 2025 | 2024 | ||||||||||||||||||||
| Americas | $ | 43,477 | 79 | % | $ | 38,112 | 78 | % | $ | 185,723 | 81 | % | $ | 152,907 | 76 | % | ||||||||
| Asia/Pacific & Europe | 11,637 | 21 | % | 10,819 | 22 | % | 42,807 | 19 | % | 47,257 | 24 | % | ||||||||||||
| Total | $ | 55,114 | 100 | % | $ | 48,931 | 100 | % | $ | 228,530 | 100 | % | $ | 200,164 | 100 | % | ||||||||
| Active Accounts (unaudited) | ||||||||||||||||||||||||
| As of June 30, | ||||||||||||||||||||||||
| 2025 | 2024 | Change from Prior Year | Percent Change | |||||||||||||||||||||
| Active Independent Consultants(1) | ||||||||||||||||||||||||
| Americas | 34,000 | 67 | % | 31,000 | 63 | % | 3,000 | 9.7 | % | |||||||||||||||
| Asia/Pacific & Europe | 17,000 | 33 | % | 18,000 | 37 | % | (1,000 | ) | (5.6 | )% | ||||||||||||||
| Total Active Independent Consultants | 51,000 | 100 | % | 49,000 | 100 | % | 2,000 | 4.1 | % | |||||||||||||||
| Active Customers(2) | ||||||||||||||||||||||||
| Americas | 66,000 | 81 | % | 63,000 | 80 | % | 3,000 | 4.8 | % | |||||||||||||||
| Asia/Pacific & Europe | 15,000 | 19 | % | 16,000 | 20 | % | (1,000 | ) | (6.3 | )% | ||||||||||||||
| Total Active Customers | 81,000 | 100 | % | 79,000 | 100 | % | 2,000 | 2.5 | % | |||||||||||||||
| Active Accounts(3) | ||||||||||||||||||||||||
| Americas | 100,000 | 76 | % | 94,000 | 73 | % | 6,000 | 6.4 | % | |||||||||||||||
| Asia/Pacific & Europe | 32,000 | 24 | % | 34,000 | 27 | % | (2,000 | ) | (5.9 | )% | ||||||||||||||
| Total Active Accounts | 132,000 | 100 | % | 128,000 | 100 | % | 4,000 | 3.1 | % | |||||||||||||||
| (1) Active Independent Consultants have purchased product in the prior three months for retail or personal consumption. | ||||||||||||||||||||||||
| (2) Active Customers have purchased product in the prior three months for personal consumption only. | ||||||||||||||||||||||||
| (3) Total Active Accounts is the sum of Active Independent Consultants and Active Customers. | ||||||||||||||||||||||||
| LIFEVANTAGE CORPORATION AND SUBSIDIARIES | |||||||||||||||
| Reconciliation of GAAP Net Income to Non-GAAP EBITDA and Non-GAAP Adjusted EBITDA: | |||||||||||||||
| (unaudited) | |||||||||||||||
| Three Months Ended June 30, | Fiscal Year Ended June 30, | ||||||||||||||
| (In thousands) | 2025 | 2024 | 2025 | 2024 | |||||||||||
| GAAP Net income (loss) | $ | 1,959 | $ | 1,305 | $ | 9,805 | $ | 2,937 | |||||||
| Interest (income) expense | (111 | ) | (78 | ) | (431 | ) | (430 | ) | |||||||
| Provision for income taxes | 437 | 1,406 | 2,438 | 1,413 | |||||||||||
| Depreciation and amortization | 750 | 805 | 3,156 | 3,581 | |||||||||||
| Non-GAAP EBITDA: | 3,035 | 3,438 | 14,968 | 7,501 | |||||||||||
| Adjustments: | |||||||||||||||
| Stock compensation expense | 1,542 | 757 | 5,702 | 3,280 | |||||||||||
| Other expense, net | (137 | ) | 277 | 387 | 412 | ||||||||||
| Other adjustments(1) | 343 | 333 | 1,054 | 5,769 | |||||||||||
| Total adjustments | 1,748 | 1,367 | 7,143 | 9,461 | |||||||||||
| Non-GAAP Adjusted EBITDA | $ | 4,783 | $ | 4,805 | $ | 22,111 | $ | 16,962 | |||||||
| (1) Other adjustments breakout: | |||||||||||||||
| Nonrecurring proxy contest related expenses, net of credits | — | (118 | ) | — | 5,043 | ||||||||||
| Executive and non-recurring severance expenses, net | 57 | 120 | 244 | 220 | |||||||||||
| Executive team recruiting and transition expenses | 38 | 198 | 562 | 198 | |||||||||||
| Other non-recurring expenses | 248 | 133 | 248 | 308 | |||||||||||
| Total adjustments | $ | 343 | $ | 333 | $ | 1,054 | $ | 5,769 | |||||||
| LIFEVANTAGE CORPORATION AND SUBSIDIARIES | |||||||||||||||
| Reconciliation of GAAP Net Income to Non-GAAP Net Income and Non-GAAP Adjusted EPS: | |||||||||||||||
| (unaudited) | |||||||||||||||
| Three Months Ended June 30, | Fiscal Year Ended June 30, | ||||||||||||||
| (In thousands) | 2025 | 2024 | 2025 | 2024 | |||||||||||
| GAAP Net income (loss) | $ | 1,959 | $ | 1,305 | $ | 9,805 | $ | 2,937 | |||||||
| Adjustments: | |||||||||||||||
| Nonrecurring proxy contest related expenses, net of credits | — | (118 | ) | — | 5,043 | ||||||||||
| Executive and non-recurring severance expenses, net | 57 | 120 | 244 | 220 | |||||||||||
| Executive team recruiting and transition expenses | 38 | 198 | 562 | 198 | |||||||||||
| Other nonrecurring expenses | 248 | 133 | 248 | 308 | |||||||||||
| Tax impact of adjustments(1) | (46 | ) | 159 | (210 | ) | (1,092 | ) | ||||||||
| Total adjustments, net of tax | 297 | 492 | 844 | 4,677 | |||||||||||
| Non-GAAP Net Income | $ | 2,256 | $ | 1,797 | $ | 10,649 | $ | 7,614 | |||||||
| Three Months Ended June 30, | Fiscal Year Ended June 30, | ||||||||||||||
| 2025 | 2024 | 2025 | 2024 | ||||||||||||
| Diluted earnings (loss) per share, as reported | $ | 0.15 | $ | 0.10 | $ | 0.75 | $ | 0.23 | |||||||
| Total adjustments, net of tax | 0.02 | 0.04 | 0.06 | 0.36 | |||||||||||
| Diluted earnings per share, as adjusted(2) | $ | 0.17 | $ | 0.14 | $ | 0.82 | $ | 0.59 | |||||||
| (1) Tax impact is based on the annual tax rate for the years ended June 30, 2025 and 2024, respectively, excluding impact of accrual from foreign income tax audits. | |||||||||||||||
| (2) May not add due to rounding. | |||||||||||||||
FAQ
What were LifeVantage's (LFVN) key financial results for fiscal year 2025?
How much cash does LifeVantage (LFVN) have on its balance sheet in 2025?
What is LifeVantage's (LFVN) revenue guidance for fiscal year 2026?
How did LifeVantage's (LFVN) international business perform in Q4 2025?
What dividend did LifeVantage (LFVN) declare in 2025?
How many shares did LifeVantage (LFVN) repurchase in fiscal 2025?
